In vivo
 212Pb/212Bi generator using indium-DTPA-tagged liposomes

Du, Alicia Le; Mougin-Degraef, Marie; Botosoa, Eliot Patrick; Rauscher, A.; Chauvet, Alexandre; Barbet, Jacques; Montavon, Gilles

doi:10.1524/ract.2011.1871

Cited by 11 publications

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides organic ligands, other carriers, such as liposomes [87] and fullerenes [34], were also considered. Such kinds of transporters can provide the absence of release of daughter radionuclides after alpha decay due to recoil.…”

Section: Ligands and Other Carriers For Pb 2+mentioning

confidence: 99%

212Pb: Production Approaches and Targeted Therapy Applications

et al. 2022

View full text Add to dashboard Cite

Over the last decade, targeted alpha therapy has demonstrated its high effectiveness in treating various oncological diseases. Lead-212, with a convenient half-life of 10.64 h, and daughter alpha-emitter short-lived 212Bi (T1/2 = 1 h), provides the possibility for the synthesis and purification of complex radiopharmaceuticals with minimum loss of radioactivity during preparation. As a benefit for clinical implementation, it can be milked from a radionuclide generator in different ways. The main approaches applied for these purposes are considered and described in this review, including chromatographic, solution, and other techniques to isolate 212Pb from its parent radionuclide. Furthermore, molecules used for lead’s binding and radiochemical features of preparation and stability of compounds labeled with 212Pb are discussed. The results of preclinical studies with an estimation of therapeutic and tolerant doses as well as recently initiated clinical trials of targeted radiopharmaceuticals are presented.

show abstract

Section: Ligands and Other Carriers For Pb 2+mentioning

confidence: 99%

212Pb: Production Approaches and Targeted Therapy Applications

et al. 2022

View full text Add to dashboard Cite

show abstract

“…There also investigations where carbon nanomaterials have been proposed for 225 Ac, 223 Ra, and 211 At radionuclides [ 89 , 91 , 92 , 102 , 105 ]. Gold nanoparticles conjugated to 211 At [ 105 , 106 ], liposomes with 212 Pb/ 212 Bi [ 107 , 108 ], and hydroxyapatite nanoparticles [ 109 ] for retention of 212 Pb have been proposed with limited success.…”

Section: Nanoradiopharmaceuticals Based On Alpha Emittersmentioning

confidence: 99%

Nanoradiopharmaceuticals Based on Alpha Emitters: Recent Developments for Medical Applications

et al. 2021

View full text Add to dashboard Cite

The application of nanotechnology in nuclear medicine offers attractive therapeutic opportunities for the treatment of various diseases, including cancer. Indeed, nanoparticles-conjugated targeted alpha-particle therapy (TAT) would be ideal for localized cell killing due to high linear energy transfer and short ranges of alpha emitters. New approaches in radiolabeling are necessary because chemical radiolabeling techniques are rendered sub-optimal due to the presence of recoil energy generated by alpha decay, which causes chemical bonds to break. This review attempts to cover, in a concise fashion, various aspects of physics, radiobiology, and production of alpha emitters, as well as highlight the main problems they present, with possible new approaches to mitigate those problems. Special emphasis is placed on the strategies proposed for managing recoil energy. We will also provide an account of the recent studies in vitro and in vivo preclinical investigations of α-particle therapy delivered by various nanosystems from different materials, including inorganic nanoparticles, liposomes, and polymersomes, and some carbon-based systems are also summarized.

show abstract

“…Montafon et al incorporated 212 Pb into indium-DTPA-tagged liposomes [98]. They found that the origin of the encapsulation is related to the dynamics of the surface, which makes the membrane partially permeable.…”

Section: Lead-212mentioning

confidence: 99%

Nanoparticles in Targeted Alpha Therapy

et al. 2020

View full text Add to dashboard Cite

Recent advances in the field of nanotechnology application in nuclear medicine offer the promise of better therapeutic options. In recent years, increasing efforts have been made on developing nanoconstructs that can be used as carriers for immobilising alpha (α)-emitters in targeted drug delivery. In this publication, we provide a comprehensive overview of available information on functional nanomaterials for targeted alpha therapy. The first section describes why nanoconstructs are used for the synthesis of α-emitting radiopharmaceuticals. Next, we present the synthesis and summarise the recent studies demonstrating therapeutic applications of α-emitting labelled radiobioconjugates in targeted therapy. Finally, future prospects and the emerging possibility of therapeutic application of radiolabelled nanomaterials are discussed.

show abstract

In vivo ²¹²Pb/²¹²Bi generator using indium-DTPA-tagged liposomes

Cited by 11 publications

References 18 publications

212Pb: Production Approaches and Targeted Therapy Applications

212Pb: Production Approaches and Targeted Therapy Applications

Nanoradiopharmaceuticals Based on Alpha Emitters: Recent Developments for Medical Applications

Nanoparticles in Targeted Alpha Therapy

Contact Info

Product

Resources

About

In vivo 212Pb/212Bi generator using indium-DTPA-tagged liposomes

Cited by 11 publications

References 18 publications

212Pb: Production Approaches and Targeted Therapy Applications

212Pb: Production Approaches and Targeted Therapy Applications

Nanoradiopharmaceuticals Based on Alpha Emitters: Recent Developments for Medical Applications

Nanoparticles in Targeted Alpha Therapy

Contact Info

Product

Resources

About

In vivo ²¹²Pb/²¹²Bi generator using indium-DTPA-tagged liposomes